Doxorubicin Injection IP 50 mg
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
Doxorubicin Injection IP 50 mg contains doxorubicin, an anthracycline cytotoxic (chemotherapy) medicine. Its labelling describes it for the treatment of several cancers, given alone or in combination with other anticancer medicines. It is described as causing the death of cancer cells by interfering with the structure of their DNA, and is administered only by a healthcare professional.
Product Information
The following description reflects information associated with doxorubicin and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described for the treatment of breast cancer
- Described for the treatment of lung cancer
- Described for the treatment of malignant lymphomas
- Described for the treatment of certain types of leukaemia
Described Dosage & Administration
- Administered only by a doctor or nurse as an injection or infusion — not self-administered
- Given alone or in combination with other anticancer medicines, at the dose and schedule set by the oncology team
- Stored in a refrigerator at 2–8°C, out of the reach and sight of children
Described Side Effects
Commonly described side effects include:
- Loss of appetite
- Nausea, vomiting, and diarrhoea
- Hair loss
- Soreness of the mouth and swelling of the ankles
- Numbness, pain, tingling, swelling, or reddening of the palms and soles
- Weight gain
- Irregular heartbeat (arrhythmia)
- Red or watery eyes with excess tear production
Effects on the heart are described as needing monitoring. Any severe, persistent, or unexpected reaction requires prompt medical attention.
Precautions
- It is described as not for use in pregnant or breastfeeding women
- The doctor should be told about any history of severe heart disorders, liver problems, or hypersensitivity, and about any previous cancer chemotherapy
- Vaccines are described as not to be given during treatment
- It is stored refrigerated at 2–8°C and kept out of the reach and sight of children
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling it contains doxorubicin, an anthracycline chemotherapy medicine used alone or with other anticancer medicines to treat several cancers, including breast cancer, lung cancer, malignant lymphomas, and certain leukaemias. SDO Pharma has not independently verified the manufacturer’s claims and does not claim any specific regulatory approval unless independently confirmed.
Its labelling states it is administered by a doctor or nurse as an injection or infusion, at the dose and schedule set by the oncology team. It is not self-administered and is stored refrigerated at 2–8°C.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.